AUS
NZ
UK
CA
USA
IND
Headlines
- Health insurer stocks declined following concerns raised by Centene about Medicaid enrollments.
- Centene's CEO highlighted ongoing challenges with Medicaid eligibility redetermination.
- Medicaid enrollments have significantly decreased since March 2023, impacting revenue for Centene.
Health insurance provider stocks saw a decline after Centene executives expressed concerns over Medicaid enrollments. Centene CEO Sarah London highlighted the ongoing impact of the Medicaid eligibility unwinding process, which continues to pressure the company's Medicaid segment.
At the Wells Fargo(NYSE:WFC) 2024 Healthcare Conference, London emphasized that the company is still experiencing challenges related to the redetermination process, which assesses who qualifies for Medicaid benefits. This process has led to a significant drop in Medicaid membership.
Centene CFO Drew Asher projected that Medicaid membership for 2024 would range between 12.9 million to 13.0 million, a decrease from earlier estimates that anticipated a rise to 13.6 million by year-end. Asher also noted that the company's current-quarter Medicaid medical costs, as a percentage of premiums, are expected to exceed those of the second quarter.
Medicaid Enrollments Experience Sharp Decline
Medicaid enrollments have decreased significantly since March 2023, according to data from the non-profit health research organization KFF. States have been unwinding their Medicaid rolls, removing those who no longer qualify. Asher mentioned that while approximately 30% of those who were terminated eventually return to Centene, the delay negatively affects the company's revenue.
Shares of Centene, along with competitors Molina Healthcare (NYSE:MOH) and Elevance (NYSE:ELV) were among the most significant decliners in the S&P 500 following these developments.
